Non-Invasive Hemodynamic Monitoring in Transcatheter Aortic Valve Implantation
<b>Background/Objectives:</b> Aortic valve stenosis (AS) is a prevalent cardiovascular condition among elderly patients frequently treated with Transcatheter Aortic Valve Implantation (TAVI). Traditional hemodynamic monitoring during TAVI relies on invasive methods. The ClearSight<sup>®</sup> Finger Cuff system offers a non-invasive alternative for continuous hemodynamic monitoring. To compare the reliability and feasibility of non-invasive hemodynamic monitoring with traditional invasive hemodynamic monitoring during TAVI procedures. <b>Methods:</b> In this prospective observational study, patients undergoing elective TAVI were recruited from two tertiary hospitals between March and August 2023. Invasive hemodynamic measurements were obtained using arterial and pigtail catheters, with a subset undergoing right heart catheterization. Non-invasive measurements were captured using the ClearSight<sup>®</sup> system. Data on baseline characteristics, procedural details, and 30-day follow-up outcomes were collected. <b>Results:</b> The study cohort comprised 50 patients (median age 82 years (IQR 78.0, 85.8), 50% female). Non-invasive measurements of cardiac output (CO), cardiac index (CI), and stroke volume (SV) were consistently lower than invasive measurements (CO: 4.1 vs. 4.8 L/min, <i>p</i> = 0.03; CI: 2.2 vs. 2.7 L/min/m<sup>2</sup>, <i>p</i> = 0.01, SV: 66 vs. 77 mL, <i>p</i> = 0.25). Non-invasive blood pressure readings were lower than invasive radial and aortic measurements before and after TAVI. Correlation of non- and invasive measurements was low but similar before and after TAVI (Mean percentage error of 52%). <b>Conclusions:</b> The ClearSight<sup>®</sup> system provided lower absolute values for all evaluated hemodynamic parameters as well as low correlation compared to traditional methods pre- as well as post-interventional.
Authors
- Gregor Leibundgut (ORCID: https://orcid.org/0000-0002-0122-5397)
- Thorald Stolte (ORCID: https://orcid.org/0000-0001-9840-7818)
- Felix Mahfoud (ORCID: https://orcid.org/0000-0002-4425-549X)
- Jakob Johannes Reichl (ORCID: https://orcid.org/0009-0007-2497-7587)
- Thomas Nestelberger (ORCID: https://orcid.org/0000-0003-2173-5738)
- Max Wagener (ORCID: https://orcid.org/0000-0002-7970-8989)
- Jasper Boeddinghaus (ORCID: https://orcid.org/0000-0003-4404-4956)
- David Wood (ORCID: https://orcid.org/0000-0001-5117-2353)
- Janarthanan Sathananthan (ORCID: https://orcid.org/0000-0001-9513-9440)
- Christoph Ado Kaiser (ORCID: https://orcid.org/0000-0002-8520-5253)
- John Webb
- Christian Schöpflin
Institutions
- University of British Columbia (CA)
- University of Basel (CH)
- St. Paul's Hospital (CA)
- University Hospital of Basel (CH)
- St. Paul's Hospital (CA)
Publication Details
- Journal
- Journal of Clinical Medicine
- Published
- 2025-05-28
- DOI
- https://doi.org/10.3390/jcm14113794
- Primary Topic
- Cardiac Valve Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Science Foundation
- Amgen
- Edwards Lifesciences
- Universität Basel
- Ortho Clinical Diagnostics
- ReCor Medical
- Universitätsspital Basel
- Deutsche Forschungsgemeinschaft
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
- Universität des Saarlandes
- Gottfried und Julia Bangerter-Rhyner-Stiftung
- Deutsche Herzstiftung
- Schweizerische Akademie der Medizinischen Wissenschaften
- Medizinische Abteilung der Margarete und Walter Lichtenstein-Stiftung
- Terumo
- Deutsche Gesellschaft für Kardiologie-Herz und Kreislaufforschung.
- Servier
- Roche Diagnostics